The Limits of High Dose Cannabinoid Therapy (HDCT)

High Dose Cannabinoid Therapy (HDCT) cannot be tolerated without allowing the body to adjust through repeated exposure to the active compounds.  Developed tolerance is especially required for the quantity of tetrahydrocannabinol (THC) used daily by an individual at the full dose levels of HDCT. (100mg oral THC 4x/day).  Thus, before HDCT can begin in earnest, it is first necessary to complete a course of increasing cannabinoid ingestion over a period of several days.  Not to do so WILL RESULT IN VIOLENT VOMITING, similar to alcohol overdose.

The Rick Simpson’s Oil (RSO) folks warn profusely in countless anecdotal counts that patients are to start with a “grain of rice” sized bit of oil and then instruct them to work their way up to one gram of “oil” per day.  Many of those patients doing their best with such an unscientific, unmeasured, unrepeatable process make themselves exceedingly ill and abandon their attempt at HDCT through no fault of their own.  This is because the cannabinoid content of RSO varies GREATLY from preparation to preparation.

Overexposure sickness and failure does not have to be the case.  Whether you are making your first attempt at HDCT ramp up or if you are one of those patients who failed on RSO you are much more likely to achieve the functional tolerance and long term success you need using the measured tabletized ramp up regimen and HDCT tablets.   Not only is the dosing more accurate, but your ramp up regimen tablets manipulate the ratio of THC to Cannabidiol (CBD) to reduce psycho activity of the THC component in the regimen.1  This is impossible with RSO.  HDCT tablets minimize the psychoactive effects of your treatment during both ramp-up phase and during full HDCT so you can spend more time being your normal self with your family, friends and at work.

Even though the CBD in your regimen (25mg oral CBD 4x/day) will mitigate the “high” of the other cannabinoids,1 all patients should expect to experience some psycho-activity from the medicine in the beginning as well as increased sleep periods.2 Plan accordingly, especially during the initial 2 weeks.  Psycho activity will diminish over time3 as your blood levels increase to the point of saturation where additional THC ingestion no longer creates a significant spike in the patient blood level. It is the spikes in THC blood levels that contribute to the “high” effect or feeling of euphoria, not the absolute quantity of THC in the blood steam which persists for days even after the last dose.4

Be patient, your body will adjust quite easily if you take the tablets as scheduled in your ramp-up package.  Allow extra time for rest as your body adjusts and avoid alcohol use especially during the ramp-up period.  Several patients report being able to tolerate a SINGLE glass of wine or other one ounce alcoholic beverage after they have completed more than a month of HDCT beyond the two week ramp-up period.  We do not however recommend this and definitely do not mix these and drive or operate other machinery.  The combination of alcohol and THC has synergistic negative impacts on driving and motor skills.5,6  Do not attempt it!  This is the time for you to ask for help from all those friends and family members who have absently asked if they could do anything to help you out.

If you are an active alcoholic you may need to be medically detoxed even BEFORE you begin HDCT ramp-up and remain alcohol free during your use of HDCT.  If this is not possible, HDCT is not a good choice.  Consult with your physician.  Excessive use of alcohol during HDCT ramp up and full dose period will certainly result in violent overuse sickness.  AVOID ALCOHOL!

For the first time, this gradual ramp up dosing and subsequent ongoing HDCT is available in a tabletized form reducing the risk of accidental overuse sickness combined with ease of ingestion.  HDCT tablets contain all of the phytocannabinoids in RSO but in a safe and more accurately dosed format that is simple to use.  The tablet granules themselves are prepared using laboratory tested alcohol extracted RSO prepared from special strains of marijuana known to produce very low levels of THC in the case of CBD dominant tablets.  In THC controlled HDCT tablets, a variety of Indica, Sativa, and hybrid strains known for high THC production are used.  The systematic dose increases of the ramp-up tablet package and their combinations virtually ensure successful development of the necessary tolerance.7 The gradually stepped THC content during your ramp-up phase minimizes the chance of overuse sickness and the consistent daily dosing once you reach the full HDCT dose helps to maintain constant blood levels of the cannabinoids.

Each whole extract tablet is controlled for either CBD or THC content, although each type may contain minor amounts of all cannabinoids.  This is by design as we are seeking an entourage effect.  This consistent dosing is important to keep constant pressure on the intracellular processes thought to interrupt the normal survival activity inside cancerous cells.  Consistent dosing is also needed to maintain your tolerance level to the HDCT full dosing levels.  If you stop taking HDCT you will need to repeat an additional ramp-up period.3 Just as your body adjusts quickly to the medicine over a period of days so too it will adjust to its pre-tolerance disposition.  Be prepared and order your refills with plenty of time allowed for delivery.

The final HDCT regimen is a 4:1, THC to Cannabidiol (CBD) ratio which also includes the full array of minor cannabinoids found in the base RSO.  Nothing is removed; only the safety and consistency are increased.  Most HDCT patients are fighting some form of cancer relying on either the anecdotal evidence they have scraped from other patients or forums and or published research showing promise of antineoplastic (anti-cancer) activity of the main active ingredients found in HDCT tablets.  Some of the cannabinoids in your HDCT tablets have even been found to be radio-sensitizing agents in certain cancers in mice,8 so HDCT may offer additional benefit if used during any treatment involving radiation therapy especially Glioma’s.  Some of the cannabinoids in HDCT tablets have also been shown to create synergistic antineoplastic activity when used in combination a certain alkylating and other chemotherapy agents in preclinical trials.9,10

You may also notice improvement in other inflammatory conditions which you have while on HDCT.  Some the cannabinoids contained in HDCT have been shown to possess anti-inflammatory effects.12–15  Cyclooxygenase enzymes are associated with the inflammatory processes in your body, the inhibition of which is the primary function of other non-steroidal anti-inflammatory drugs like aspirin, ibuprofen, acetaminophen and naproxen.  The main cannabinoids in HDCT have been shown to block the production of cyclooxygenase enzymes.  Don’t be surprised if your arthritis, colitis, or any of your “itis” inflammatory conditions improve on this regimen.11

Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. Neuropsychopharmacology. 2009;35(3):764-774. doi: 10.1038/npp.2009.184
Gorelick DA, Goodwin RS, Schwilke E, et al. Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. The American Journal on Addictions. 2013;22(5):510-514. doi: 10.1111/j.1521-0391.2013.12003.x
Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice. Drug and Alcohol Dependence. 2000;60(2):113-119. doi: 10.1016/s0376-8716(99)00150-7 [Source]
Odell M, Frei M, Gerostamoulos D, Chu M, Lubman D. Residual cannabis levels in blood, urine and oral fluid following heavy cannabis use. Forensic Sci Int. 2015;249:173-180. [PubMed]
Bosker WM, Kuypers KPC, Theunissen EL, et al. Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012;107(10):1837-1844. doi: 10.1111/j.1360-0443.2012.03928.x
Perez-Reyes M, Hicks RE, Bumberry J, Robert Jeffcoat A, Cook CE. Interaction between Marihuana and Ethanol: Effects on Psychomotor Performance. Alcoholism: Clinical and Experimental Research. 1988;12(2):268-276. doi: 10.1111/j.1530-0277.1988.tb00193.x
Russo L. Cannabinoid Poisoning. Medscape. Published June 24, 2016. Accessed October 25, 2016.
Scott KA, Dalgleish AG, Liu WM. The Combination of Cannabidiol and  9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model. Molecular Cancer Therapeutics. 2014;13(12):2955-2967. doi: 10.1158/1535-7163.mct-14-0402
Torres S, Lorente M, Rodriguez-Fornes F, et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Molecular Cancer Therapeutics. 2011;10(1):90-103. doi: 10.1158/1535-7163.mct-10-0688
Nabissi M, Morelli MB, Santoni M, Santoni G. Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis. 2012;34(1):48-57. doi: 10.1093/carcin/bgs328
Ruhaak L, Felth J, Karlsson P, Rafter J, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull. 2011;34(5):774-778. [PubMed]
Malfait A, Gallily R, Sumariwalla P, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561-9566. [PubMed]
Wirth PW, Sue Watson E, ElSohly M, Turner CE, Murphy JC. Anti-inflammatory properties of cannabichromene. Life Sciences. 1980;26(23):1991-1995. doi: 10.1016/0024-3205(80)90631-1 [Source]
Burstein S, Zurier R. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J. 2009;11(1):109-119. [PubMed]
Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(3):294-299. [PubMed]

Leave a Reply